Furthermore, other clinical studies of dendritic cell vaccine loaded with WT1 peptides in combination with chemotherapy in patients with advanced pancreatic cancer have confirmed the safety of administration of the vaccine and suggested that the antiproliferative effect on the tumor and the survival-promoting effect were greater in patients with a positive immune response [17, 18]. Here, WT1 is linked to familial pancreatic carcinoma.